600535 Tasly Pharmaceutical Group
- 13.23
- +0.10+0.76%
Tasly Pharmaceutical Group News
Announcement from Tasly Pharmaceutical Group regarding the extension of employee shareholding plan.
Announcement from Tasly Pharmaceutical Group regarding its subsidiary's acquisition of pharmaceutical registration certificate.
Announcement of Tasly Pharmaceutical Group's wholly-owned subsidiary Pharmaceutical Fumarate Ketotifen Tablets passing the generic consistency evaluation.
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders of Tasly
Legal Opinion of Inner Mongolia Jianzhong Law Firm on the 2023 Annual General Meeting of Shareholders of Tianshili Pharmaceutical Group Co., Ltd.
Tessile 2023 Annual General Meeting of Shareholders Meeting Materials
Report on the performance of supervisory duties by the Audit Committee of the Board of Directors of Tasman in 2023
Tianshili's Notice on Convening the 2023 Annual General Meeting of Shareholders
Tianshili's 2023 Audit Committee Performance Report
Tianshili's announcement on the selection of staff representative supervisors of the 9th Board of Supervisors
Tianshili 2023 Internal Control Evaluation Report
Tianshili's announcement that its wholly-owned subsidiary drug Nicordil tablets passed the generic drug consistency evaluation
Announcement of Resolutions of Tasly\'s 2024 First Extraordinary General Meeting of Shareholders
Legal Opinion of Inner Mongolia Jianzhong Law Firm on the 2024 First Extraordinary General Meeting of Shareholders of Tianshili Pharmaceutical Group Co., Ltd.
Tianshili\'s Announcement on Reducing Registered Capital and Notifying Creditors
Meeting materials of Tasly\'s 2024 First Extraordinary General Meeting of Shareholders
Tianshili\'s announcement on changing registered capital and amending the “Articles of Association”
Tianshili Certified Public Accountants Selection and Employment System
Tianshili\'s Articles of Association (revised in December 2023)
Notice of Tasly\'s 2024 First Extraordinary General Meeting of Shareholders
Analysis
Price Target
No Data
